COMP <GO>
ROIV vs UTHR // EV/EBITDA & P/E VALUATION
Roivant Sciences Ltd. (NASDAQ) VS. United Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: ROIV 3
— UTHR 8
■ METRIC PARITY
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
valuation
—
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
valuation
12.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. UTHR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | UTHR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 87.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 20.10% | -34.10 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 12.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 4.09% | -6.89 | UTHR | /fcf-yield <GO> |
| Operating Margin | -60.00% | 46.90% | -106.90 | UTHR | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 41.90% | -101.90 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 10.60% | -75.60 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 22.52 | +3.48 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 66.9 | -9.70 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.95 | +0.05 | ROIV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 17.8x | +10.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $25.46B | $1.64B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | UTHR REV | ROIV GROSS % | UTHR GROSS % | ROIV FCF | UTHR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $3.18B | — | 87.9% | -$758.6M | $1.04B |
| FY 2024 | $29.1M | $2.88B | — | 89.2% | -$844.0M | $1.08B |
| FY 2023 | $32.7M | $2.33B | — | — | -$766.7M | $873.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
UTHR // BETA 0.95